AI and RWD Integration: Transforming Clinical Trials and Drug Development
CorEvitas is now part of Thermo Fisher Scientific. Read More.
-
During a panel discussion held at DIA Global 2024, industry experts discussed how AI and real-world data (RWD) are accelerating drug development.
Experts from Evidera and PPD highlighted the potential of AI and real-world data in transforming the landscape of clinical trials, from optimizing trial design to enhancing patient-centric studies. The panel emphasized the importance of collaboration and regulatory support to maximize the potential of advanced technologies in drug development. The panel discussion was moderated by Peter Wahl, Vice President and Global Head of Scientific Affairs at CorEvitas.